4D pharma’s Blautix® Phase II Clinical Trial Results Published in Alimentary Pharmacology & Therapeutics
Traders Cafe with Zak Mir: Bulletin Board Heroes, Tuesday 15th November 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, BSF,
Traders Cafe with Zak Mir: Bulletin Board Heroes, Tuesday 8th November 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is FTSE 100, Dax, Dow, Bitcoin, Aston,
RAF jets shoot down 53 drones in the largest air-to-air missile mass-firing exercise
Three RAF airfields hosted Typhoon and Lightning fighter planes. One pilot described the experience as “fantastic”.
4d Pharma PLC (AIM:DDDD) MRx0518 poster presentations at SITC 2022
4D pharma Announces Two Presentations at The Society for Immunotherapy of Cancer Annual Meeting (SITC 2022)
4d Pharma PLC (AIM:DDDD) Update on Suspension of Trading on AIM – Delay to publication of Interim Results
Leeds, UK, September 28, 2022 , – 4D pharma plc (AIM: DDDD), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from
4d Pharma PLC (AIM:DDDD) Publication of preclinical autism research
4D pharma Announces Publication of Preclinical Research Showing Live Biotherapeutic MRx0006 Efficacy in Animal Model of Autism Spectrum Disorder
4d Pharma PLC (AIM:DDDD) Temporary Suspension
Leeds, UK, 24 June 2022 , – 4D pharma plc (AIM: DDDD, Nasdaq LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug
4d Pharma PLC (AIM:DDDD) ASCO 2022 MRx0518 and Bavencio Trial In Progress
4D pharma Presents Trial in Progress Poster on the Phase II Study of MRx0518 in Combination with BAVENCIO® in Patients with Unresectable Locally Advanced or Metastatic Urothelial Carcinoma at the
4d Pharma PLC (AIM:DDDD) ATS 2022 – MRx-4DP0004 Phase I/II Part A poster
4D pharma Presents Late-Breaking Abstract from Phase I/II Trial of MRx-4DP0004 for the Treatment of Asthma at the American Thoracic Society (ATS) 2022 International Conference
RNS Hotlist with Zak Mir: ORPH, ECR, ARB, RMM, OEX, LVCG, ATOM, TLY, PYC, IMM, BOD, SDX, RBD, KOD, ETX, CGNR, ANR, SHNJ & DNM
Open Orphan (ORPH), a specialist contract research organisation said it noted market speculation regarding a potential delisting. The company confirmed that it has no plans to delist and is working
Traders Cafe with Zak Mir: Bulletin Board Heroes, Monday 25th April 2022 via Vox Markets
Zak Mir takes a charting look at some of the most followed small caps on the London stock market. Today’s selection of charts is Boston, Drumz, Empire, Genedrive, Keras, Live,